A novel approach to predict cetuximab-induced hypersensitivity reaction: detection of drug-specific IgE on basophils

Cancer Medicine

Volumn 5, Issue 6, 2016, Pages 1004-1012

  Iwamoto, Takuya ^a   Okamoto, Akiharu ^a   Ishinaga, Hajime ^b   Shimizu, Kasumi ^b   Gayle, Alberto A ^b   Arai, Naoya ^b   Takeuchi, Kazuhiko ^b   Okuda, Masahiro ^a  

^a MIE UNIVERSITY HOSPITAL   (Japan)

^b MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antibody drugs; biomarkers; drug allergy; head and neck cancer

Indexed keywords

CETUXIMAB; GALACTOSYLGALACTOSE; IMMUNOGLOBULIN E;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; BASOPHIL; CLINICAL ARTICLE; CONTROLLED STUDY; DISSOCIATION; DRUG BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK FACTOR; VERY ELDERLY;

EID: 84991522888     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.658     Document Type: Article

References (31)

1. Company B-MS. ERBITUX® (cetuximab) injection. 2013.
2. Cunningham, D., Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, et al. 2004. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 351:337–45.
3. Bonner, J. A., P. M. Harari, J. Giralt, N. Azarnia, D. M. Shin, R. B. Cohen, et al. 2006. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 354:567–78.
4. Vermorken, J. B., R. Mesia, F. Rivera, E. Remenar, A. Kawecki, S. Rottey, et al. 2008. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 359:1116–27.
5. Pirker, R., J. R. Pereira, A. Szczesna, J. von Pawel, M. Krzakowski, R. Ramlau, et al. 2009. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 373:1525–31.
6. Galvao, V. R. and M. C., CastellsHypersensitivity to biological agents-updated diagnosis, management, and treatment. J Allergy Clin Immunol Pract. 2015; 3: 175–85; quiz 86.
7. O'Neil, B. H., R. Allen, D. R. Spigel, T. E. Stinchcombe, D. T. Moore, J. D. Berlin, et al. 2007. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol. 25:3644–8.
8. Keating, K., C. Walko, B. Stephenson, B. H. O'Neil, and J. Weiss. 2014. Incidence of cetuximab-related infusion reactions in oncology patients treated at the University of North Carolina Cancer Hospital. J Oncol Pharm Pract. 20:409–16.
9. Dupont, B., D. Mariotte, C. Moldovan, J. M. Grellard, M. C. Vergnaud, D. Laroche, et al. 2014. Case Report About Fatal or Near-Fatal Hypersensitivity Reactions to Cetuximab: Anticetuximab IgE as a Valuable Screening Test. Clin Med Insights Oncol. 8:91–4.
10. Maier, S., C. H. Chung, M. Morse, T. Platts-Mills, L. Townes, P. Mukhopadhyay, et al. 2015. A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions. Cancer medicine. 4:36–42.
11. Sampson, H. A. 2003. Anaphylaxis and emergency treatment. Pediatrics. 111:1601–8.
12. Chung, C. H., B. Mirakhur, E. Chan, Q. T. Le, J. Berlin, M. Morse, et al. 2008. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 358:1109–17.
13. Platts-Mills, T. A., A. J. Schuyler, A. Tripathi, and S. P. Commins. 2015. Anaphylaxis to the carbohydrate side chain alpha-gal. Immunol Allergy Clin North Am. 35:247–60.
14. Mariotte, D., B. Dupont, R. Gervais, M. P. Galais, D. Laroche, A. Tranchant, et al. 2011. Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis. MAbs. 3:396–401.
15. Boumiza, R., A. L. Debard, and G. Monneret. 2005. The basophil activation test by flow cytometry: recent developments in clinical studies, standardization and emerging perspectives. Clin Mol Allergy. 3:9.
16. MacGlashan, D. Jr. 2010. Expression of CD203c and CD63 in human basophils: relationship to differential regulation of piecemeal and anaphylactic degranulation processes. Clin Exp Allergy. 40:1365–77.
17. Hennersdorf, F., S. Florian, A. Jakob, K. Baumgartner, K. Sonneck, A. Nordheim, et al. 2005. Identification of CD13, CD107a, and CD164 as novel basophil-activation markers and dissection of two response patterns in time kinetics of IgE-dependent upregulation. Cell Res. 15:325–35.
18. Chirumbolo, S., A. Vella, R. Ortolani, M. De Gironcoli, P. Solero, G. Tridente, et al. 2008. Differential response of human basophil activation markers: a multi-parameter flow cytometry approach. Clin Mol Allergy. 6:12.
19. Michel, S., K. Scherer, I. A. Heijnen, and A. J. Bircher. 2014. Skin prick test and basophil reactivity to cetuximab in patients with IgE to alpha-gal and allergy to red meat. Allergy. 69:403–5.
20. Nagao, M., Y. Hiraguchi, K. Hosoki, R. Tokuda, T. Usui, S. Masuda, et al. 2008. Allergen-induced basophil CD203c expression as a biomarker for rush immunotherapy in patients with Japanese cedar pollinosis. Int Arch Allergy Immunol. 146(Suppl 1):47–53.
21. Tanaka, A., T. Tanaka, H. Suzuki, K. Ishii, Y. Kameyoshi, and M. Hide. 2006. Semi-purification of the immunoglobulin E-sweat antigen acting on mast cells and basophils in atopic dermatitis. Exp Dermatol. 15:283–90.
22. Suzuki, H., Y. Yanase, T. Tsutsui, K. Ishii, T. Hiragun, and M. Hide. 2008. Applying surface plasmon resonance to monitor the IgE-mediated activation of human basophils. Allergol Int. 57:347–58.
23. Iwamoto, T., H. Hirai, N. Yamaguchi, N. Kobayashi, H. Sugimoto, T. Tabata, et al. 2014. Carboplatin-induced severe hypersensitivity reaction: role of IgE-dependent basophil activation and FcepsilonRI. Cancer Sci. 105:1472–9.
24. Takai, T., K. Takahashi, M. Akagawa-Chihara, M. Fukada, T. Yuuki, I. Shibuya, et al. 2001. Production of humanized antibody against human high-affinity IgE receptor in a serum-free culture of CHO cells, and purification of the Fab fragments. Bioscience, biotechnology, and biochemistry. 65:1082–9.
25. Sturm, G. J., C. Schuster, B. Kranzelbinder, M. Wiednig, A. Groselj-Strele, and W. Aberer. 2009. Asymptomatic sensitization to hymenoptera venom is related to total immunoglobulin E levels. Int Arch Allergy Immunol. 148:261–4.
26. Piva, E., F. Chieco-Bianchi, V. Krajcar, S. Aversa, and M. Plebani. 2012. Adverse reactions in patients with B-cell lymphomas during combined treatment with rituximab: In vitro evaluation of rituximab hypersensitivity by basophil activation test. Am J Hematol. 87:E130–1.
27. Commins, S. P., H. R. James, W. Stevens, S. L. Pochan, M. H. Land, C. King, et al. 2014. Delayed clinical and ex vivo response to mammalian meat in patients with IgE to galactose-alpha-1,3-galactose. J Allergy Clin Immunol. 134:108–15.
28. Iwamoto, T., A. Yuta, T. Tabata, H. Sugimoto, E. C. Gabazza, H. Hirai, et al. 2012. Evaluation of basophil CD203c as a predictor of carboplatin-related hypersensitivity reaction in patients with gynecologic cancer. Biol Pharm Bull. 35:1487–95.
29. Balzer, L., D. Pennino, S. Blank, H. Seismann, U. Darsow, M. Schnedler, et al. 2014. Basophil activation test using recombinant allergens: highly specific diagnostic method complementing routine tests in wasp venom allergy. PLoS One. 9:e108619.
30. Cassard, L., F. Jonsson, S. Arnaud, and M. Daeron. 2012. Fcgamma receptors inhibit mouse and human basophil activation. Journal of immunology. 189:2995–3006.
31. Siena, S., R, G.-J., A. Adenis, J. Thaler, P. Preusser, E. A. Aguilar, et al. Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication. Cancer. 2010; 116: 1827–37.